|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RAD51C |
Gene summary for RAD51C |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RAD51C | Gene ID | 5889 |
| Gene name | RAD51 paralog C | |
| Gene Alias | BROVCA3 | |
| Cytomap | 17q22 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | O43502 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5889 | RAD51C | LZE2T | Human | Esophagus | ESCC | 8.78e-04 | 5.56e-01 | 0.082 |
| 5889 | RAD51C | LZE4T | Human | Esophagus | ESCC | 4.07e-09 | 2.83e-01 | 0.0811 |
| 5889 | RAD51C | LZE5T | Human | Esophagus | ESCC | 1.64e-04 | 2.28e-01 | 0.0514 |
| 5889 | RAD51C | LZE7T | Human | Esophagus | ESCC | 2.72e-06 | 5.81e-01 | 0.0667 |
| 5889 | RAD51C | LZE8T | Human | Esophagus | ESCC | 4.75e-02 | 1.26e-01 | 0.067 |
| 5889 | RAD51C | LZE22T | Human | Esophagus | ESCC | 8.74e-04 | 2.56e-01 | 0.068 |
| 5889 | RAD51C | LZE24T | Human | Esophagus | ESCC | 1.30e-16 | 4.60e-01 | 0.0596 |
| 5889 | RAD51C | LZE21T | Human | Esophagus | ESCC | 1.40e-03 | 4.76e-01 | 0.0655 |
| 5889 | RAD51C | LZE6T | Human | Esophagus | ESCC | 3.80e-07 | 4.51e-01 | 0.0845 |
| 5889 | RAD51C | P1T-E | Human | Esophagus | ESCC | 1.21e-15 | 4.73e-01 | 0.0875 |
| 5889 | RAD51C | P2T-E | Human | Esophagus | ESCC | 3.41e-36 | 5.06e-01 | 0.1177 |
| 5889 | RAD51C | P4T-E | Human | Esophagus | ESCC | 3.64e-21 | 3.29e-01 | 0.1323 |
| 5889 | RAD51C | P5T-E | Human | Esophagus | ESCC | 8.05e-13 | 1.48e-01 | 0.1327 |
| 5889 | RAD51C | P8T-E | Human | Esophagus | ESCC | 5.95e-29 | 4.83e-01 | 0.0889 |
| 5889 | RAD51C | P9T-E | Human | Esophagus | ESCC | 8.61e-12 | 2.56e-01 | 0.1131 |
| 5889 | RAD51C | P10T-E | Human | Esophagus | ESCC | 1.59e-30 | 5.01e-01 | 0.116 |
| 5889 | RAD51C | P11T-E | Human | Esophagus | ESCC | 5.50e-04 | 2.83e-01 | 0.1426 |
| 5889 | RAD51C | P12T-E | Human | Esophagus | ESCC | 2.43e-36 | 5.63e-01 | 0.1122 |
| 5889 | RAD51C | P15T-E | Human | Esophagus | ESCC | 2.67e-18 | 3.87e-01 | 0.1149 |
| 5889 | RAD51C | P16T-E | Human | Esophagus | ESCC | 1.32e-31 | 4.88e-01 | 0.1153 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00008194 | Esophagus | ESCC | sister chromatid segregation | 157/8552 | 202/18723 | 8.41e-21 | 1.33e-18 | 157 |
| GO:000705911 | Esophagus | ESCC | chromosome segregation | 238/8552 | 346/18723 | 1.72e-18 | 1.82e-16 | 238 |
| GO:004477216 | Esophagus | ESCC | mitotic cell cycle phase transition | 281/8552 | 424/18723 | 4.63e-18 | 4.45e-16 | 281 |
| GO:000734615 | Esophagus | ESCC | regulation of mitotic cell cycle | 293/8552 | 457/18723 | 8.00e-16 | 5.64e-14 | 293 |
| GO:00482853 | Esophagus | ESCC | organelle fission | 301/8552 | 488/18723 | 4.64e-13 | 2.12e-11 | 301 |
| GO:00988133 | Esophagus | ESCC | nuclear chromosome segregation | 187/8552 | 281/18723 | 1.00e-12 | 4.36e-11 | 187 |
| GO:000072319 | Esophagus | ESCC | telomere maintenance | 99/8552 | 131/18723 | 2.68e-12 | 1.08e-10 | 99 |
| GO:00002802 | Esophagus | ESCC | nuclear division | 270/8552 | 439/18723 | 1.17e-11 | 4.24e-10 | 270 |
| GO:190198713 | Esophagus | ESCC | regulation of cell cycle phase transition | 242/8552 | 390/18723 | 3.86e-11 | 1.26e-09 | 242 |
| GO:190199013 | Esophagus | ESCC | regulation of mitotic cell cycle phase transition | 191/8552 | 299/18723 | 1.35e-10 | 3.94e-09 | 191 |
| GO:004578710 | Esophagus | ESCC | positive regulation of cell cycle | 196/8552 | 313/18723 | 9.27e-10 | 2.24e-08 | 196 |
| GO:00448394 | Esophagus | ESCC | cell cycle G2/M phase transition | 103/8552 | 148/18723 | 3.09e-09 | 6.67e-08 | 103 |
| GO:00000864 | Esophagus | ESCC | G2/M transition of mitotic cell cycle | 96/8552 | 137/18723 | 6.00e-09 | 1.23e-07 | 96 |
| GO:004593116 | Esophagus | ESCC | positive regulation of mitotic cell cycle | 83/8552 | 121/18723 | 2.78e-07 | 4.08e-06 | 83 |
| GO:00063024 | Esophagus | ESCC | double-strand break repair | 152/8552 | 251/18723 | 1.33e-06 | 1.62e-05 | 152 |
| GO:19019896 | Esophagus | ESCC | positive regulation of cell cycle phase transition | 77/8552 | 115/18723 | 3.20e-06 | 3.58e-05 | 77 |
| GO:00900689 | Esophagus | ESCC | positive regulation of cell cycle process | 142/8552 | 236/18723 | 4.79e-06 | 5.08e-05 | 142 |
| GO:00103891 | Esophagus | ESCC | regulation of G2/M transition of mitotic cell cycle | 64/8552 | 94/18723 | 9.21e-06 | 8.82e-05 | 64 |
| GO:19027491 | Esophagus | ESCC | regulation of cell cycle G2/M phase transition | 68/8552 | 102/18723 | 1.48e-05 | 1.33e-04 | 68 |
| GO:003220014 | Esophagus | ESCC | telomere organization | 99/8552 | 159/18723 | 1.77e-05 | 1.57e-04 | 99 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RAD51C | SNV | Missense_Mutation | c.1078N>C | p.Glu360Gln | p.E360Q | O43502 | protein_coding | tolerated_low_confidence(0.13) | benign(0.143) | TCGA-A8-A09I-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD | |
| RAD51C | SNV | Missense_Mutation | c.421N>C | p.Asp141His | p.D141H | O43502 | protein_coding | deleterious(0) | probably_damaging(0.928) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| RAD51C | SNV | Missense_Mutation | c.61N>T | p.Pro21Ser | p.P21S | O43502 | protein_coding | tolerated(0.16) | benign(0.043) | TCGA-BH-A209-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| RAD51C | SNV | Missense_Mutation | rs752608224 | c.61N>G | p.Pro21Ala | p.P21A | O43502 | protein_coding | tolerated(0.32) | benign(0.031) | TCGA-D8-A1JD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| RAD51C | SNV | Missense_Mutation | c.954N>A | p.Asp318Glu | p.D318E | O43502 | protein_coding | tolerated(0.93) | benign(0.003) | TCGA-D8-A1Y0-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cyclophosphamide+methotrexatum+fluorouracillum | SD | |
| RAD51C | SNV | Missense_Mutation | rs773998134 | c.106N>A | p.Glu36Lys | p.E36K | O43502 | protein_coding | tolerated(0.24) | benign(0.044) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
| RAD51C | SNV | Missense_Mutation | c.238G>C | p.Glu80Gln | p.E80Q | O43502 | protein_coding | tolerated(0.56) | benign(0.02) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| RAD51C | SNV | Missense_Mutation | c.175N>A | p.Glu59Lys | p.E59K | O43502 | protein_coding | deleterious(0) | possibly_damaging(0.688) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| RAD51C | SNV | Missense_Mutation | novel | c.1023N>G | p.Ile341Met | p.I341M | O43502 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-VS-A8QF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| RAD51C | SNV | Missense_Mutation | c.760N>T | p.Asp254Tyr | p.D254Y | O43502 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-A6-6141-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fu | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |